Neoadjuvant Chemotherapy in Breast Cancer: The NSABP B-18 trial (1998) by Fisher et al. demonstrated that preoperative chemotherapy could shrink tumors, leading to more lumpectomies. #BreastCancer #Oncology #PathSky #MedSky #breastpath pubmed.ncbi.nlm.nih.gov/9704717/

Gene Expression Profiling Leading to Molecular Subtypes of Breast Cancer: Perou et al. (2000) published in Nature gave us the Luminal A/B, HER2-enriched, and Basal-like classifications. #MolecularBiology #BreastCancer #BreastPathology #PathSky #BreastOncology pubmed.ncbi.nlm.nih.gov/10963602/

The Tamoxifen Trial. Fisher et al. (1989) in the New England Journal of Medicine showed us the power of hormone therapy in ER+ breast cancer—a landmark study that revolutionized breast cancer treatment protocols. pubmed.ncbi.nlm.nih.gov/2644532/ #BreastCancer #BreastOncology #Pathology #PathSky

Understanding HER2 in Breast Cancer: Slamon et al.'s 1987 study on HER2/neu amplification paved the way for targeted therapies like Herceptin. #HER2Positive #BreastCancer pubmed.ncbi.nlm.nih.gov/3798106/

Estrogen Receptor in Breast Carcinoma. Remmele & Stegner's 1987 study revolutionized how we diagnose and treat breast carcinoma by identifying ER by immunohistochemistry. #BreastCancer #BreastPath pubmed.ncbi.nlm.nih.gov/3303008/

I’ll try something new on Bluesky and post small summaries of landmark papers in breast cancer. Discovering the BRCA1 Gene: A Game-Changer in Breast Cancer Genetics. Miki et al. (1994) opened new avenues for understanding hereditary breast cancer. #BreastCancer pubmed.ncbi.nlm.nih.gov/7545954/